CYP2C19, cytochrome P450 family 2 subfamily C member 19, 1557
N. diseases: 274; N. variants: 14
Source: ALL
Disease | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year |
---|---|---|---|---|---|---|---|
|
0.100 | Biomarker | disease | BEFREE | Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. | 12132671 | 2002 |
|
0.100 | GeneticVariation | disease | BEFREE | Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. | 21361732 | 2011 |
|
0.100 | GeneticVariation | disease | BEFREE | Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy. | 30403784 | 2019 |
|
0.100 | GeneticVariation | disease | BEFREE | Twenty-five white patients were genotyped for CYP2C19 by allele-specific polymerase chain reaction amplification, and their Helicobacter pylori status was assessed by serology and with immunoblot analysis. | 10982760 | 2000 |
|
0.100 | GeneticVariation | disease | BEFREE | The present study aimed to assess the effects of CYP2C19 gene polymorphisms on proton pump inhibitor (PPI), amoxicillin, and levofloxacin triple therapy for Helicobacter pylori (Hp) eradication. | 28577017 | 2017 |
|
0.100 | GeneticVariation | disease | BEFREE | Simultaneous detection of human CYP2C19 polymorphisms and antibiotic resistance of Helicobacter pylori using a personalised diagnosis kit. | 29444465 | 2018 |
|
0.100 | GeneticVariation | disease | BEFREE | In this study, we examined the usefulness of the prediction of the pharmacotherapeutic efficacy using a newly developed analysis system for HP CAM resistance and CYP2C19 genotypes. | 21132257 | 2011 |
|
0.100 | GeneticVariation | disease | BEFREE | But no study correlated CYP2C19 genetic polymorphism with eradication of Helicobacter pylori in north Indian gastritis patients positive for H. pylori and hence this study. | 19942749 | 2009 |
|
0.100 | GeneticVariation | disease | BEFREE | CYP2C19*2, *3, *4, *5 and *17 genotypes were determined in healthy Helicobacter pylori-negative Caucasian subjects. | 19785625 | 2010 |
|
0.100 | GeneticVariation | disease | BEFREE | Methods : We determined CYP2C19 genotypes (CYP2C19*1, *2 and *3) in 111 Helicobacter pylori-positive patients with gastric cancer and 315 H. pylori-positive controls without gastric cancer consisting of patients with gastritis only or peptic ulcer. | 16268979 | 2005 |
|
0.100 | Biomarker | disease | BEFREE | Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia. | 27706745 | 2016 |
|
0.100 | GeneticVariation | disease | BEFREE | We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole- or esomeprazole-based triple therapy. | 18637061 | 2008 |
|
0.100 | GeneticVariation | disease | BEFREE | Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. | 24599773 | 2014 |
|
0.100 | GeneticVariation | disease | BEFREE | Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. | 19552744 | 2009 |
|
0.100 | GeneticVariation | disease | BEFREE | Our aim was to investigate prophylaxis effects of famotidine, one of the representative histamine-2 receptor antagonists (H2RA), on gastric mucosal injury induced by dual therapy with low-dose aspirin and clopidogrel in relation to Helicobacter pylori (H. pylori) infection and CYP2C19 genotypes. | 24615745 | 2014 |
|
0.100 | Biomarker | disease | BEFREE | We intended to determine SNPs of CYP2C19 and 23S rRNA of Helicobacter pylori by using rapid urease test (RUT)-positive gastric mucosal samples. | 15952098 | 2005 |
|
0.100 | GeneticVariation | disease | BEFREE | To investigate whether MDR1 polymorphism is associated with eradication rates of Helicobacter pylori by a triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP2C19 genotype status and bacterial susceptibility to clarithromycin. | 17697203 | 2007 |
|
0.100 | GeneticVariation | disease | BEFREE | It has been suggested that proton pump inhibitor (PPI)-related differences in Helicobacter pylori eradication rates are partly because of CYP2C19 polymorphisms and there have been conflicting data in this area. | 16863547 | 2006 |
|
0.100 | Biomarker | disease | BEFREE | MeSH terms and keywords included proton pump inhibitor, omeprazole, lansoprazole, rabeprazole, pantoprazole, or esomeprazole, cytochrome P4502C19 or CYP2C19, and Helicobacter pylori or H. pylori. | 19166419 | 2008 |
|
0.100 | Biomarker | disease | BEFREE | Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. | 15691303 | 2005 |
|
0.100 | GeneticVariation | disease | BEFREE | Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study. | 27221874 | 2016 |
|
0.100 | Biomarker | disease | BEFREE | The known factors that have contributed to the decline of Helicobacter pylori (H. pylori) eradication rate include antibiotic resistance, poor compliance, high gastric acidity, high bacterial load, and cytochrome P450 2C19 (CYP2C19) polymorphism. | 25473155 | 2014 |
|
0.100 | GeneticVariation | disease | BEFREE | To investigate the effect of different proton pump inhibitors, S-mephenytoin 4'-hydroxylase (CYP2C19) genotype and antibiotic susceptibility on the eradication rate of Helicobacter pylori. | 12534411 | 2003 |
|
0.100 | GeneticVariation | disease | BEFREE | Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy. | 30859680 | 2019 |
|
0.100 | GeneticVariation | disease | BEFREE | Both clarithromycin-resistant Helicobacter pylori and CYP2C19 polymorphisms may be passed down for generations and are known risk factors for the failure of H. pylori eradication therapy. | 31264254 | 2019 |